ClinicalTrials.gg
RecruitingNCT06938152Updated Jun 23, 2026

Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients

A Phase 4 interventional study of Romosozumab followed by Denosumab and Romosozumab and Denosumab Cycle Therapy in Osteoporosis and Osteoporosis Postmenopausal, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to female participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-06-23.

Primary conditionOsteoporosis, PostmenopausalRegistry: OsteoporosisReclassifiedWhy we changed it
Registry
Osteoporosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Osteoporosis, Postmenopausal
Why
  1. The study's listed conditions name Osteoporosis, Postmenopausal, a narrower term within Osteoporosis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Taiwan University Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
Female
01

Study summary

This study is a prospective, randomized, controlled clinical trial comparing the efficacy of a 24-month cyclic therapy regimen (6 months of Romosozumab followed by 6 months of Denosumab, repeated for two years) versus a traditional sequential treatment regimen (12 months of Romosozumab followed by 12 months of Denosumab). The goal is to determine which approach yields better therapeutic outcomes and to optimize drug strategies for osteoporosis patients.

Read the detailed description

Osteoporosis is common in postmenopausal women and the elderly, and has been recognized by the World Health Organization as the second most prevalent metabolic bone disease worldwide. Most patients show no obvious symptoms, but a fall or sudden exertion can cause fragility fractures. Once fractures occur, complications such as acute pain, prolonged bed rest, and restricted mobility can significantly impact the quality of life and even increase mortality. Furthermore, managing these conditions requires substantial medical and social resources.

Currently, anti-osteoporosis medications are classified into two major categories: antiresorptive and anabolic agents. Studies have confirmed that both types can increase bone mineral density (BMD) and reduce fracture risk. However, each medication has usage limitations.

Denosumab is a potent antiresorptive drug, but long-term use can lead to rare side effects such as atypical femoral fractures (AFF) and medication-related osteonecrosis of the jaw (MRONJ). Additionally, stopping Denosumab can cause a severe rebound in bone resorption markers (CTX), leading to rapid BMD loss and an increased fracture risk. Managing drug discontinuation remains a major clinical challenge.

02

Conditions studied

  • Osteoporosis
  • Osteoporosis Postmenopausal

Browse trials for

Keywords

  • postmenopausal
  • Romosozumab
  • Denosumab
  • cycle therapy
  • Bone mineral density
  • Bone turnover marker
03

In context

Osteoporosis, Postmenopausal Reclassified

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

This study's planned enrollment of 70 is below the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.

Browse Osteoporosis, Postmenopausal studies →

Lead sponsor

National Taiwan University Hospital is the lead sponsor of 2,617 studies on the registry; 575 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.

Compared within Osteoporosis, Postmenopausal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Osteoporosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. women aged 50-90 years
  • 2. BMD T-score ≤ -3.0 at any lumbar vertebra
  • 3. Physically and mentally capable of understanding and complying with the study protocol and follow-up
  • 4. Signed

Exclusion criteria

Exclusion Criteria:

  • 1. Previous osteoporosis treatment within the past two years, including Romosozumab, Teriparatide, Denosumab, Alendronate, Ibandronate, Zoledronic Acid, Risedronate, Raloxifene, or Bazedoxifene
  • 2. Allergy to Romosozumab or Denosumab
  • 3. Secondary osteoporosis
  • 4. disease
  • 5. Chronic use (e.g., Chronic Obstruction Pulmonary Disease patients)
  • 6. Hypercalcemia or hypocalcemia
  • 7. Metabolic bone diseases
  • 8. Primary or bone tumors
  • 9. Cancer patients (except for in situ carcinoma and non-melanoma skin cancer, unless fully treated and in remission for five years)
  • 10. Planned dental procedures (e.g., extractions, implants) within the next year
  • 11. History of stent placement, myocardial infarction, stroke, or coronary artery disease
  • 12. Renal disease (Creatinine > 1.5 mg/dL) or dialysis patients
  • 13. Smoking more than one pack per day (except for those who have quit for over ten years)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Sequential therapy group

    Romosozumab followed by Denosumab

    Drug: Romosozumab followed by Denosumab

  • Experimental
    Cycle therapy group

    Romosozumab and Denosumab Cycle Therapy

    Drug: Romosozumab and Denosumab Cycle Therapy

Interventions

  • DrugRomosozumab followed by Denosumab

    Drug pages: RomosozumabStudies of RomosozumabRomosozumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · DenosumabStudies of DenosumabDenosumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Romosozumab 210mg/month for 12 months, then Denosumab 60mg/6months for 12 months

    Also known as: Sequential therapy group

  • DrugRomosozumab and Denosumab Cycle Therapy

    Romosozumab 210mg/month for 6 months then followed by Denosumab 60mg/6months once, and then repeat one more time after 6 months

    Also known as: Cycle therapy group

06

What researchers measure

Primary outcomes

  1. Change in bone mineral density (BMD)

    Change in BMD at lumbar spine, femoral neck and total hip at 24 months

    Time frame: Participants will undergo baseline assessments, followed by evaluations at 6, 12, 18 and 24 months.

Secondary outcomes

  1. Change in bone turnover makers (BTM) level

    Changes in BTM, including bone formation (P1NP) and resorption markers (CTX)

    Time frame: Participants will undergo baseline assessments, followed by evaluations at 3, 6, 9, 12, 13, 15, 18, 21, and 24 months.

  2. Change in visual Analogue Scale (VAS) score

    The Visual Analogue Scale (VAS) for pain will be used to assess participants' self-reported pain intensity. The VAS score ranges from 0 to 10, higher scores indicate worse pain intensity, and lower scores indicate less pain.

    Time frame: Participants will undergo baseline assessments, followed by evaluations at 3, 6, 9, 12, 15, 18, 21, and 24 months.

  3. Oswestry Disability Index (ODI) score change

    The Oswestry Disability Index (ODI) will be used to assess the level of disability related to lower back pain. The ODI score ranges from 0 to 100, higher scores reflect worse functional disability and lower scores reflect better functional status.

    Time frame: Participants will undergo baseline assessments, followed by evaluations at 6, 12, 18 and 24 months.

  4. New fracture

    Any new fracture within 24 months

    Time frame: During the intervention period, up to 24 months.

  5. Adverse Events

    Any adverse events

    Time frame: During the intervention period, up to 24 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Kobayakawa T, Miyazaki A, Takahashi J, Nakamura Y. Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study. Bone. 2022 Sep;162:116480. doi: 10.1016/j.bone.2022.116480. Epub 2022 Jul 1. PubMed 35787482 ↗
  • Hong N, Shin S, Kim H, Cho SJ, Park JA, Rhee Y. Romosozumab following denosumab improves lumbar spine bone mineral density and trabecular bone score greater than denosumab continuation in postmenopausal women. J Bone Miner Res. 2025 Feb 2;40(2):184-192. doi: 10.1093/jbmr/zjae179. PubMed 39485918 ↗
  • Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016 Oct 20;375(16):1532-1543. doi: 10.1056/NEJMoa1607948. Epub 2016 Sep 18. PubMed 27641143 ↗
  • Chandran M. The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence. Arch Endocrinol Metab. 2022 Nov 11;66(5):724-738. doi: 10.20945/2359-3997000000564. PubMed 36382762 ↗
  • Gehrke B, Alves Coelho MC, Brasil d'Alva C, Madeira M. Long-term consequences of osteoporosis therapy with bisphosphonates. Arch Endocrinol Metab. 2023 Nov 10;68:e220334. doi: 10.20945/2359-4292-2022-0334. PubMed 37948565 ↗
  • McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int. 2017 May;28(5):1723-1732. doi: 10.1007/s00198-017-3919-1. Epub 2017 Jan 31. PubMed 28144701 ↗
  • Cosman F, Huang S, McDermott M, Cummings SR. Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses. J Bone Miner Res. 2022 Nov;37(11):2112-2120. doi: 10.1002/jbmr.4705. Epub 2022 Oct 12. PubMed 36088628 ↗
  • Reid IR, Billington EO. Drug therapy for osteoporosis in older adults. Lancet. 2022 Mar 12;399(10329):1080-1092. doi: 10.1016/S0140-6736(21)02646-5. PubMed 35279261 ↗
  • LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022 Oct;33(10):2049-2102. doi: 10.1007/s00198-021-05900-y. Epub 2022 Apr 28. PubMed 35478046 ↗
  • Fogelman I, Blake GM. Different approaches to bone densitometry. J Nucl Med. 2000 Dec;41(12):2015-25. PubMed 11138687 ↗
  • Wang CY, Wu CH, Chen HM, Lin JW, Hsu CC, Chang YF, Tai TW, Fu SH, Hwang JS. Cost and effectiveness analyses of the anti-osteoporosis medication in patients with hip fracture in Taiwan: A population-based national claims database analysis. J Formos Med Assoc. 2023;122 Suppl 1:S92-S100. doi: 10.1016/j.jfma.2023.07.018. Epub 2023 Aug 11. PubMed 37574339 ↗
  • Wang CY, Fu SH, Yang RS, Shen LJ, Wu FL, Hsiao FY. Age- and gender-specific epidemiology, treatment patterns, and economic burden of osteoporosis and associated fracture in Taiwan between 2009 and 2013. Arch Osteoporos. 2017 Oct 25;12(1):92. doi: 10.1007/s11657-017-0385-5. PubMed 29067572 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Apr 2029, 48 months after the start.

Of 27 phase 4 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's planned 48 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2025
First posted
Apr 22, 2025
StartActual
Apr 8, 2025
Primary completionEst.
Apr 30, 2029
CompletionEst.
Dec 31, 2029
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06938152
Responsible party
Sponsor
First posted
Apr 22, 2025
Start date
Apr 8, 2025
Primary completion
Apr 30, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Jun 23, 2026

Study contacts

Fon-Yih Tsuang
Contact
k880113a@gmail.com
886-2312-3456 ext. 265956

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion